See more : Eregli Demir ve Çelik Fabrikalari T.A.S. (EREGL.IS) Income Statement Analysis – Financial Results
Complete financial analysis of AVITA Medical, Inc. (RCEL) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of AVITA Medical, Inc., a leading company in the Medical – Devices industry within the Healthcare sector.
You may be interested
- Fluor Corporation (FLR) Income Statement Analysis – Financial Results
- Prismo Metals Inc. (PRIZ.CN) Income Statement Analysis – Financial Results
- Vision Lithium Inc. (VLI.V) Income Statement Analysis – Financial Results
- Jibannet Holdings Co., Ltd. (6072.T) Income Statement Analysis – Financial Results
- Vulcan Energy Resources Limited (VULNF) Income Statement Analysis – Financial Results
AVITA Medical, Inc. (RCEL)
About AVITA Medical, Inc.
AVITA Medical Inc. operates as a commercial-stage regenerative tissue company in the United States, Australia, and the United Kingdom. It offers regenerative products to address unmet medical needs in burn injuries, trauma injuries, chronic wounds, and dermatological and aesthetics indications, including vitiligo. The company's patented and proprietary platform technology provides treatment solutions derived from the regenerative properties of a patient's own skin. Its lead product is RECELL System, a device that enables healthcare professionals to produce a suspension of Spray-On Skin cells using a small sample of the patient's own skin for use in the treatment of acute thermal burns in patients eighteen years and older. The company has a research collaboration with the University of Colorado School of Medicine to establish pre-clinical proof-of-concept for a spray-on treatment of genetically corrected cells; and a research collaboration with Houston Methodist Research Institute to explore molecular reversal of cellular aging through a novel cell suspension delivery system. The company was formerly known as AVITA Therapeutics, Inc. and changed its name to AVITA Medical Inc. in December 2020. AVITA Medical Inc. was incorporated in 2000 and is based in Valencia, California.
| Metric | 2022 | 2020 | 2019 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 50.56M | 14.26M | 20.67M | 1.26M | 1.18M | 1.00M | 985.65K | 2.68M | 2.81M | 3.35M | 3.34M | 2.30M | 2.37M | 1.20M | 790.99K | 883.39K | 389.08K | 194.32K | 0.00 | 0.00 | 0.00 | 582.97K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 8.87M | 2.97M | 4.31M | 737.70K | 505.64K | 401.57K | 289.20K | 670.89K | 676.50K | 952.85K | 972.78K | 669.45K | 824.23K | 492.31K | 1.13M | 1.06M | 940.26K | 98.98K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 41.69M | 11.29M | 16.36M | 517.47K | 675.00K | 600.44K | 696.45K | 2.01M | 2.14M | 2.40M | 2.36M | 1.63M | 1.54M | 711.35K | -337.70K | -176.85K | -551.18K | 95.34K | 0.00 | 0.00 | 0.00 | 582.97K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 82.45% | 79.16% | 79.16% | 41.23% | 57.17% | 59.92% | 70.66% | 75.00% | 75.97% | 71.58% | 70.84% | 70.85% | 65.18% | 59.10% | -42.69% | -20.02% | -141.66% | 49.06% | 0.00% | 0.00% | 0.00% | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 20.35M | 8.46M | 13.28M | 8.45M | 6.27M | 3.46M | 3.77M | 2.15M | 2.60M | 969.11K | 255.54K | 164.79K | 181.85K | 163.83K | 620.67K | 1.33M | 425.97K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 34.27M | 34.62M | 46.77M | 12.70M | 0.00 | 6.51M | 2.45M | 4.27M | 5.45M | 5.34M | 5.42M | 3.40M | 3.87M | 3.98M | 5.36M | 5.64M | 2.21M | 725.90K | 480.40K | 569.49K | 235.70K | 371.78K | 97.16K | 138.81K | 126.55K | 278.48K | 207.93K |
| Selling & Marketing | 32.19M | 14.81M | 22.76M | 6.59M | 5.20M | 3.46M | 3.21M | 2.63M | 3.39M | 2.93M | 2.15M | 1.15M | 1.37M | 1.39M | 1.92M | 1.90M | 838.56K | 122.35K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 66.46M | 49.43M | 70.61M | 21.21M | 13.90M | 10.93M | 5.68M | 7.09M | 8.92M | 8.44M | 7.57M | 4.55M | 5.24M | 5.37M | 7.28M | 7.54M | 3.05M | 848.25K | 480.40K | 569.49K | 235.70K | 371.78K | 97.16K | 138.81K | 126.55K | 278.48K | 207.93K |
| Other Expenses | 0.00 | 686.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 852.27K | 886.45K | 41.73K | 5.88K | 4.27M | 85.29K | 240.35K | -1.28M | -24.61K | -2.08M | 28.27K | -956.00K | -1.56M | 1.52M | 910.39K | 40.34K | 16.93K |
| Operating Expenses | 80.78M | 53.97M | 77.21M | 19.15M | 13.35M | 11.95M | 9.26M | 8.83M | 10.77M | 10.66M | 7.89M | 5.23M | 5.91M | 5.75M | 8.75M | 9.62M | 4.87M | 169.38K | 670.01K | 76.87K | 235.70K | 371.78K | 97.16K | 138.81K | 126.55K | 278.48K | 207.93K |
| Cost & Expenses | 89.65M | 56.94M | 81.51M | 19.88M | 13.85M | 12.36M | 9.55M | 9.50M | 11.45M | 11.61M | 8.86M | 5.90M | 6.74M | 6.25M | 9.88M | 10.68M | 5.81M | 268.36K | 670.01K | 76.87K | 235.70K | 371.78K | 97.16K | 138.81K | 126.55K | 278.48K | 207.93K |
| Interest Income | 23.50K | 0.00 | 47.82K | 28.37K | 110.96K | 110.34K | 45.42K | 160.33K | 412.26K | 497.99K | 124.99K | 124.70K | 270.11K | 668.21K | 543.41K | 520.50K | 201.65K | 145.15K | 126.13K | 195.94K | 6.81K | 609.80 | 4.20K | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 33.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 12.90K | 37.65K | 78.50K | 53.20K | 8.55M | 4.86K | 9.95K | 2.26K | 3.57 | 4.97M | 576.36K | 2.07M | 2.19M | 258.33K | 1.16M | 775.70 | -191.00K |
| Depreciation & Amortization | 1.46M | 465.00K | 0.00 | 105.45K | 139.70K | 83.72K | 62.62K | 63.71K | 121.92K | 569.23K | 650.88K | 517.57K | 491.49K | 221.96K | 852.62K | 745.94K | 702.81K | 111.83K | 189.60K | 76.87K | 595.35K | -923.38K | -2.19M | 578.99K | -1.16M | -1.96M | 49.44K |
| EBITDA | -39.57M | -41.53M | -61.17M | -18.55M | -12.53M | -11.27M | -8.68M | -6.76M | -8.51M | -5.62M | -3.89M | -2.08M | -3.57M | -4.15M | -3.69M | -8.45M | -4.27M | -1.39M | -390.45K | 575.84K | 359.65K | 582.97K | -2.29M | 440.17K | -1.29M | -2.23M | -158.49K |
| EBITDA Ratio | -78.26% | -291.16% | -295.97% | -1,478.04% | -1,061.34% | -1,124.79% | -880.69% | -251.79% | -302.36% | -167.75% | -116.76% | -90.46% | -150.78% | -344.42% | -466.58% | -956.13% | -1,097.89% | -717.25% | 0.00% | 0.00% | 0.00% | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -40.40M | -42.68M | -61.84M | -18.70M | -12.67M | -11.35M | -8.74M | -6.82M | -8.63M | -6.19M | -4.38M | -2.59M | -4.06M | -4.37M | -4.54M | -9.19M | -4.97M | -1.62M | -1.29M | 498.37K | -235.70K | 1.51M | -97.16K | -138.81K | -126.55K | -278.48K | -207.93K |
| Operating Income Ratio | -79.91% | -299.23% | -299.23% | -1,489.88% | -1,073.17% | -1,133.14% | -887.04% | -254.16% | -306.69% | -184.73% | -131.31% | -113.00% | -171.55% | -362.86% | -574.37% | -1,040.57% | -1,278.53% | -832.34% | 0.00% | 0.00% | 0.00% | 258.39% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 1.29M | 686.00K | 946.20K | 43.24K | 110.96K | 110.34K | 222.97K | 160.33K | 412.26K | -1.57M | 3.23M | -1.82M | 41.73K | -7.58M | -4.55M | 85.29K | 240.35K | -1.58M | -735.53K | -1.16M | -567.08K | -956.00K | -1.56M | 1.52M | 911.13K | 99.29K | 158.49K |
| Income Before Tax | -39.12M | -42.03M | -60.90M | -18.66M | -12.56M | -11.24M | -8.52M | -6.66M | -8.22M | -7.76M | -2.18M | -5.34M | -4.14M | -12.00M | -13.09M | -9.20M | -4.98M | -1.51M | -1.29M | -1.63M | -812.06K | -563.08K | -2.29M | 184.42K | -1.29M | -2.18M | -16.93K |
| Income Before Tax Ratio | -77.36% | -294.65% | -294.65% | -1,486.44% | -1,063.77% | -1,122.13% | -864.42% | -248.18% | -292.04% | -231.47% | -65.24% | -232.33% | -174.86% | -997.23% | -1,655.44% | -1,041.12% | -1,281.08% | -775.96% | 0.00% | 0.00% | 0.00% | -96.59% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 52.88K | 4.00K | 5.80K | 1.45M | 1.05M | 971.88K | 653.67K | 1.51M | 128.05K | 87.76K | -90.09K | -330.41K | 78.50K | -342.23K | -316.55K | -311.92K | -7.13M | -2.69M | -2.53M | -2.94M | 576.36K | -923.38K | 2.19M | -581.57K | 1.16M | -238.92K | 208.61K |
| Net Income | -39.17M | -42.03M | -60.90M | -17.21M | -11.51M | -10.27M | -7.87M | -5.15M | -8.09M | -7.59M | -2.09M | -5.01M | -4.14M | -11.66M | -12.78M | -8.89M | -4.98M | -1.54M | -1.12M | -1.54M | -812.06K | -562.85K | -2.29M | 184.42K | -1.29M | -1.94M | -225.54K |
| Net Income Ratio | -77.47% | -294.68% | -294.68% | -1,370.83% | -974.99% | -1,025.14% | -798.10% | -191.84% | -287.49% | -226.42% | -62.54% | -217.95% | -174.86% | -968.80% | -1,615.42% | -1,005.81% | -1,281.08% | -794.76% | 0.00% | 0.00% | 0.00% | -96.55% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -1.57 | -2.07 | -3.00 | -1.84 | -1.72 | -2.06 | -2.23 | -1.58 | -2.69 | -3.19 | -1.53 | -3.93 | -3.75 | -16.51 | -3.24 | -3.43 | -3.14 | -1.92 | -0.56 | -0.80 | -1.32 | -2.25 | -48.58 | -0.74 | -27.28 | -42.11 | -5.06 |
| EPS Diluted | -1.57 | -2.07 | -3.00 | -1.85 | -1.72 | -2.06 | -2.23 | -1.58 | -2.69 | -3.19 | -1.53 | -3.93 | -3.75 | -16.51 | -3.24 | -3.43 | -3.14 | -1.92 | -0.56 | -0.80 | -1.32 | -2.25 | -48.58 | -0.74 | -27.28 | -42.11 | -5.06 |
| Weighted Avg Shares Out | 25.00M | 20.29M | 20.29M | 9.30M | 6.69M | 4.99M | 3.53M | 3.25M | 3.01M | 2.38M | 1.36M | 1.27M | 1.10M | 706.45K | 3.94M | 2.59M | 1.59M | 806.03K | 2.00M | 1.93M | 614.53K | 249.70K | 47.13K | 47.13K | 47.13K | 46.02K | 44.55K |
| Weighted Avg Shares Out (Dil) | 25.00M | 20.29M | 20.29M | 9.33M | 6.70M | 4.99M | 3.53M | 3.25M | 3.01M | 2.38M | 1.36M | 1.27M | 1.10M | 706.45K | 3.94M | 2.59M | 1.59M | 806.03K | 2.00M | 1.93M | 614.53K | 249.70K | 47.13K | 47.13K | 47.13K | 46.02K | 44.55K |
AVITA Medical to Participate at the Lake Street 2021 BIG5 Conference
VALENCIA, Calif., and MELBOURNE, Australia, Aug. 31, 2021 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs,...
AVITA Medical, Inc.'s (RCEL) CEO Mike Perry on Q4 2021 Results - Earnings Call Transcript
AVITA Medical, Inc.'s (RCEL) CEO Mike Perry on Q4 2021 Results - Earnings Call Transcript
AVITA Medical Announces Inclusion in the Russell 3000 Index
VALENCIA, Calif. and MELBOURNE, Australia, June 29, 2021 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs,...
RCEL Stock Price Increases Over 19% Pre-Market: Why It Happened
The stock price of AVITA Medical Inc (NASDAQ: RCEL) increased by over 19% pre-market. This is why it happened.
AVITA Medical Announces Preliminary Fourth Quarter 2021 Financial Results
VALENCIA, Calif. and MELBOURNE, Australia, June 15, 2021 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs,...
AVITA Medical Gains FDA Expanded Labels In 'Better Mousetrap' Burn Treatment
The RECELL system gained FDA approval for pediatric and large surface area burns.
AVITA Medical, Inc. Appoints Two New Non-Executive Members to the Board of Directors
VALENCIA, Calif. and MELBOURNE, Australia, June 01, 2021 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (Nasdaq: RCEL; ASX: AVH) (“AVITA Medical”), a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for multiple...
AVITA: Recell's Growing Upside
Avita shareholders' indecisive earnings reaction provided an excellent buying opportunity. The company's pivotal trial delays are disappointing.
AVITA Medical's (RCEL) CEO Mike Perry on Q3 2021 Results - Earnings Call Transcript
AVITA Medical's (RCEL) CEO Mike Perry on Q3 2021 Results - Earnings Call Transcript
All You Need to Know About AVITA Medical, Inc. (RCEL) Rating Upgrade to Buy
AVITA Medical, Inc. (RCEL) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Source: https://incomestatements.info
Category: Stock Reports